Positive Cardiometabolic Health Resource

An intervention framework for people experiencing psychosis and schizophrenia

This clinical resource supports the implementation of the physical health CQUIN http://www.england.nhs.uk/wp-content/uploads/2014/02/sc-cquin-guid.pdf (page 36) which aims to improve collaborative and effective physical health monitoring of patients experiencing severe mental illness. It focusses on antipsychotic medication for adults, but many of the principles can be applied to other psychotropic medicines given to adults with long term mental disorders, e.g. mood stabilisers.

For all patients in the “red zone” (see center page spread): The general practitioner, psychiatrist and patient will work together to ensure appropriate monitoring and interventions are provided and communicated. The general practitioner will usually lead on supervising the provision of physical health interventions. The psychiatrist will usually lead on decisions to significantly change antipsychotic medication.


The following organisations support the use of this resource:
Royal College of Psychiatrists (RCPsych)
Royal College of General Practitioners (RCGP)
Royal College of Physicians
Royal College of Nursing
Royal College of Surgeons (RC Surgeons)
UK Faculty of Public Health (FPH)
UCL Partners – Academic Health Science Partnership
Healthcare Quality Improvement Partnership (HQIP)
National Collaborating Centre for Mental Health (NCCMH)
Diabetes UK
Rethink Mental Illness

Download Lester UK Adaptation: www.rcpsych.ac.uk/quality/NAS/resources
An intervention framework for people experiencing psychosis and schizophrenia

**Positive Cardiometabolic Health Resource**

**Smoking**
- Current smoker

**Lifestyle and Life Skills**
- Poor diet AND/OR
- Sedentary lifestyle

**Body Mass Index (BMI)**
- BMI ≥25 kg/m²
- (≥23 kg/m² if South Asian or Chinese)

**Blood Pressure**
- >140 mm Hg systolic
- AND/OR
- >90 mm Hg diastolic

**Glucose Regulation**
- HbA1c or Glucose threshold:
  - HbA1c ≥42 mmol/mol (≥6%)
  - AND/OR
  - FPG ≥5.5 mmol/l
  - OR
  - RPG ≥11.1 mmol/l

**Blood Lipids**
- Total chol/HDL ratio to detect high (>10%) risk of CVD based on QRISK-2 Tool
  - http://qrisk.org/
  - Note: CVD risk scores can underestimate risk in those with psychosis

**Medication review and lifestyle advice to include diet and physical activity**
- NB Family history of diabetes and/or premature heart disease heightens cardiometabolic risk.

**Refer for investigation, diagnosis and treatment by appropriate clinician if necessary.**

**Smoking**
- Brief intervention
  - Combined NRT and/or varenicline
  - Individual/group behavioral support or specialist support if high dependency
  - Referral to Smoking Cessation service

**Lifestyle and Life Skills**
- Follow NICE guidelines for obesity
  - http://www.nice.org.uk/CN43

**Blood Pressure**
- Follow NICE hypertension guidelines
  - http://publications.nice.org.uk/hypertension-cg127
  - Consider anti-hypertensive therapy
  - Limit salt intake in diet

**Glucose Regulation**
- At High Risk of Diabetes
  - HbA1c 42-47 mmol/mol (6.0% - 6.4%)
  - FPG 5.5 - 6.9 mmol/l
  - i) Offer intensive structured lifestyle education programme
  - ii) If ineffective consider metformin

**Blood Lipids**
- Follow NICE guidelines for lipid modification AND
  - Refer to specialist if total cholesterol >9, non-HDL chol >7.5 or TG>20 (mmol/l)
  - AND
  - Consider lipid modification for those with CVD or Diabetes

**Defining BMI**
- BMI 18.5-24.9 kg/m²
  - (18.5-22.9 kg/m² if South Asian or Chinese)

**Target blood pressure**
- <140/90 mm Hg
  - (≤130/80 mm Hg for those with CVD or diabetes)

**Target fasting plasma glucose (FPG)**
- <5.5 mmol/l

**Target HbA1c**
- <42 mmol/mol (≤6%)

**Primary Prevention:**
- Consider statin treatment if ≥10% risk based on QRISK2
  - OR
  - Secondary Prevention: aim to reduce non-HDL chol by 40% and review in 3 months
History and examination following initiation or change of antipsychotic medication

**Frequency:** Normally supervised by the psychiatrist. As a minimum review those prescribed a new antipsychotic at baseline and at least once after 3 months. Weight should be assessed weekly in the first six weeks of taking a new antipsychotic, as rapid early weight gain may predict severe weight gain in the longer term. Subsequent reviews should take place annually unless an abnormality of physical health emerges. In these cases, appropriate action should be taken and/or the situation should be reviewed at least every 3 months.

**At review**

**History:** Seek history of substantial weight gain (e.g. 5kg), especially where this has been rapid (e.g. within 3 months). Also review smoking, exercise and diet. Ask about family history (diabetes, obesity, CVD in first degree <55 yrs male relatives and <65 yrs female relatives) and gestational diabetes. Note ethnicity.

**Examination:** Weight, BMI, BP, pulse.

**Investigations:** Fasting estimates of plasma glucose (FPG), HbA1c, and lipids (total cholesterol, non-HDL, HDL, triglycerides). If fasting samples are impractical then non-fasting samples are satisfactory for most measurements except for triglycerides.

**ECG:** Include if history of CVD, family history of CVD; where examination reveals irregular pulse (if ECG confirms atrial fibrillation, follow NICE recommendations [http://guidance.nice.org.uk/CG36](http://guidance.nice.org.uk/CG36)); or if patient taking certain antipsychotics (See SPC) or other drugs known to cause ECG abnormalities (eg erythromycin, tricyclic anti-depressants, anti-arrhythmics – see British National Formulary for further information).

**Chronic Kidney Disease**

Screen those with co-existing diabetes, hypertension, CVD, family history of chronic kidney disease, structural renal disease (e.g. renal stones) routinely:

1. Monitor renal function: a) urea & electrolytes
   b) estimated glomerular filtration rate (eGFR)

2. Test urine: a) for proteinuria (dip-stick), b) albumin creatinine ratio (laboratory analysis)

*Presence of chronic kidney disease additionally increases risk of CVD: follow appropriate NICE guidelines on chronic kidney disease.

**Monitoring: How often and what to do**

Applies to patients prescribed antipsychotics and mood stabilizers.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Weekly first 6 weeks</th>
<th>12 weeks</th>
<th>Annually</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal/FHx</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifestyle Review†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist circumference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPG/HbA1c</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lipid Profile</strong>‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†Smoking, diet, and physical activity  ‡If fasting lipid profile cannot be obtained, a non-fasting sample is satisfactory


**Specific lifestyle and pharmacological interventions**

Specific lifestyle interventions should be discussed in a collaborative, supportive and encouraging way, taking into account the person’s preferences:

- **Nutritional counselling:** reduce take-away and “junk” food, reduce energy intake to prevent weight gain, avoid soft and caffeinated drinks and juices, and increase fibre intake.

- **Physical activity:** structured education-lifestyle intervention. Advise physical activity such as a minimum of 150 minutes of ‘moderate-intensity’ physical activity per week ([http://bit.ly/Oe7DeS](http://bit.ly/Oe7DeS)). For example suggest 30 minutes of physical activity on 5 days a week.

If the patient has not successfully reached their targets after 3 months, consider specific pharmacological interventions:


**Treatment of those at high risk of diabetes:** FPG 5.5-6.9 mmol/l, Hba1c; 42-47 mmol/mol (6.0-6.4%) Follow NICE guideline PH38 Preventing type 2 diabetes: risk identification and interventions for individuals at high risk (recommendation 19) – [http://guidance.nice.org.uk/PH38](http://guidance.nice.org.uk/PH38).

- Where intensive lifestyle intervention has failed consider a metformin trial (normally be GP supervised).

- Please be advised that off-label use requires documented informed consent as described in the GMP guidelines, [http://www.gmp-uk.org/guidance/ethical_guidance/14327.asp](http://www.gmp-uk.org/guidance/ethical_guidance/14327.asp). These GMC guidelines are recommended by the MPS and MDU, and the use of metformin in this context has been agreed as a relevant example by the Defence Unions.

- Adhere to British National Formulary guidance on safe use (in particular ensure renal function is adequate).

- Start with a low dose e.g 500mg once daily and build up, as tolerated, to 1500–2000mg daily.

**Review of antipsychotic and mood stabiliser medication:**

Discussions about medication should involve the patient, the general practitioner and the psychiatrist. Should be a priority if there is:

- Rapid weight gain (e.g. 5kg <3 months) following antipsychotic initiation.

- Rapid development (<3 months) of abnormal lipids, BP, or glucose.

The psychiatrist should consider whether the antipsychotic drug regimen has played a causative role in these abnormalities and, if so, whether an alternative regimen could be expected to offer less adverse effects:

- As a first step prescribed dosages should follow BNF recommendations; rationalise any polypharmacy.

- Changing antipsychotic medication requires careful clinical judgment to weigh any benefits against the risk of relapse of the psychosis.

- An effective trial of medication is considered to be the patient taking the medication, at an optimum dosage, for a period of 4-6 weeks.

- If clinical judgment and patient preference support continuing with the same treatment, then ensure appropriate further monitoring and clinical considerations are carried out regularly.

It is advised that all side effects to antipsychotic medication are regularly monitored, especially when commencing a new antipsychotic medication (GASS questionnaire [http://mentalhealthpartnerships.com/resource/glasgow-antipsychotic-side-effect-scale/](http://mentalhealthpartnerships.com/resource/glasgow-antipsychotic-side-effect-scale/)), and that any side effects, as well as the rationale for continuing, changing or stopping medication is clearly recorded and communicated with the patient.

The Psychiatrist should maintain responsibility for monitoring the patient’s physical health and the effects of anti-psychotic medication for at least the first 12 months or until the person’s condition has stabilised, whichever is longer. Thereafter, the responsibility for this monitoring may be transferred to primary care under shared care arrangements.

Discuss any non-prescribed therapies the patient wishes to use (including complementary therapies) with the patient, and carer if appropriate. Discuss the safety and efficacy of the therapies, and possible interference with the therapeutic effects of prescribed medication and psychological treatments.